International Standard Serial Number (issn): 2319-8141 International Journal of Universal Pharmacy and Bio Sciences Therapeutic Potential of Nicorandil International Standard Serial Number (issn): 2319-8141

Scientific studies describing the Dead Sea treatments and products leave no doubt that for most conditions which have shown to respond to this mode of therapy, this natural treatment has major advantages by being: Remarkably effective, practically free of side effects both during and after the treatment even for refractory cases, suitable for children and for pregnant women, with only very few contraindications, safe, pleasant and well accepted.

[1]  S. Shibata,et al.  The inhibitory mechanisms of nicorandil in isolated rat urinary bladder and femoral artery. , 1995, European journal of pharmacology.

[2]  N. Di Girolamo,et al.  Nicorandil inhibits the release of TNFalpha from a lymphocyte cell line and peripheral blood lymphocytes. , 2003, International immunopharmacology.

[3]  K. Fox,et al.  Potassium channel openers in myocardial ischaemia: therapeutic potential of nicorandil. , 2001, Drugs.

[4]  D. Harder,et al.  Possible cellular mechanism for cerebral vasospasm after experimental subarachnoid hemorrhage in the dog. , 1987, The Journal of clinical investigation.

[5]  Yun Xia,et al.  Cerebral protective effect of nicorandil premedication on patients undergoing liver transplantation. , 2012, Hepatobiliary & pancreatic diseases international : HBPD INT.

[6]  W. Baumgartner,et al.  Nicorandil prevents oxidative stress-induced apoptosis in neurons by activating mitochondrial ATP-sensitive potassium channels , 2003, Brain Research.

[7]  K. Fox,et al.  Cardioprotection by opening of the KATPchannel in unstable anginaIs this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil , 1999 .

[8]  S. Dkhar,et al.  Potassium channels in health, disease & development of channel modulators. , 2009, The Indian journal of medical research.

[9]  Y. Okumura,et al.  Effect of the ATP-sensitive K⁺ channel opener nicorandil in a canine model of proarrhythmia. , 2011, International heart journal.

[10]  H. Hayakawa,et al.  Reduction of Size of Myocardial Infarction with Nicorandil, a New Antianginal Drug, After Coronary Artery Occlusion in Dogs , 1988, Journal of cardiovascular pharmacology.

[11]  I. Takeyoshi,et al.  The effect of nicorandil on ischemia-reperfusion injury in a porcine total hepatic vascular exclusion model. , 2011, The Journal of surgical research.

[12]  R. Mann,et al.  Safety profile of nicorandil—prescription‐event monitoring (PEM) study , 1999, Pharmacoepidemiology and drug safety.

[13]  P. Thomas,et al.  Nicorandil inhibits degranulation and TNF-α release from RBL-2H3 cells , 2002, Inflammation Research.

[14]  A. Yamada,et al.  Nicorandil inhibits oxidative stress-induced apoptosis in cardiac myocytes through activation of mitochondrial ATP-sensitive potassium channels and a nitrate-like effect. , 2003, Journal of molecular and cellular cardiology.

[15]  H. Nagai,et al.  Effect of three novel K+ channel openers, cromakalim, pinacidil and nicorandil on allergic reaction and experimental asthma. , 1992, Japanese journal of pharmacology.

[16]  A. Terzic,et al.  K(ATP) channel therapeutics at the bedside. , 2005, Journal of molecular and cellular cardiology.

[17]  S. Archer.  Potassium channels and erectile dysfunction. , 2002, Vascular pharmacology.

[18]  R. Bruno,et al.  Pharmacokinetics of nicorandil. , 1989, The American journal of cardiology.

[19]  P. Quandalle,et al.  Potassium channel activators in vasospastic angina. , 1993, European heart journal.

[20]  K. Nithipatikom,et al.  Infarct size-reducing effect of nicorandil is mediated by the KATP channel but not by its nitrate-like properties in dogs. , 1996, Cardiovascular research.

[21]  M. Reilly,et al.  Increased formation of the isoprostanes IPF2alpha-I and 8-epi-prostaglandin F2alpha in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. , 1997, Circulation.

[22]  T. Murohara,et al.  Impact of a Single Intravenous Administration of Nicorandil Before Reperfusion in Patients With ST-Segment–Elevation Myocardial Infarction , 2005, Circulation.

[23]  M. Arai,et al.  Nicorandil reduces myocardial infarct size by opening the K(ATP) channel in rabbits. , 1997, International journal of cardiology.

[24]  H. Ishizaka,et al.  Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. , 2004, American heart journal.

[25]  G. De Sarro,et al.  Potential role of potassium channel openers in the treatment of asthma and chronic obstructive pulmonary disease. , 2002, Life sciences.

[26]  K. Goa,et al.  Nicorandil , 2012, Drugs.

[27]  Y. Taniyama,et al.  Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. , 1999, Journal of the American College of Cardiology.

[28]  K. Fujiwara,et al.  Scavenging effect of nicorandil on free radicals and lipid peroxide in streptozotocin-induced diabetic rats. , 2000, Metabolism: clinical and experimental.

[29]  D. Praticò,et al.  8-Epi PGF2α Generation During Coronary Reperfusion , 1997 .

[30]  K. Wellington,et al.  Nicorandil , 2012, Drugs.

[31]  G. Gross,et al.  Anti-free-radical and neutrophil-modulating properties of the nitrovasodilator, nicorandil , 1992, Cardiovascular Drugs and Therapy.

[32]  T. Kunihara,et al.  The adenosine triphosphate-sensitive potassium channel opener nicorandil protects the ischemic rabbit spinal cord. , 2001, The Journal of thoracic and cardiovascular surgery.

[33]  H. Pass,et al.  Alterations in macrophage free radical and tumor necrosis factor production by a potassium channel activator. , 1992, The Journal of surgical research.

[34]  D. Warltier,et al.  Cardioprotective Effects of Nicorandil , 1992, Journal of cardiovascular pharmacology.

[35]  Guozhong Shi,et al.  Electrophysiologic Effects of Nicorandil on the Guinea Pig Long QT1 Syndrome Model , 2004, Journal of cardiovascular electrophysiology.

[36]  S. L. Allen,et al.  The relaxant action of nicorandil in guinea‐pig isolated trachealis , 1986, British journal of pharmacology.

[37]  M. Arita,et al.  Antiarrhythmic Effects of Nicorandil on Canine Cardiac Purkinje Fibers , 1984, Journal of cardiovascular pharmacology.

[38]  K. Shimamoto,et al.  Infarct size limitation by nicorandil: roles of mitochondrial K(ATP) channels, sarcolemmal K(ATP) channels, and protein kinase C. , 2002, Journal of the American College of Cardiology.

[39]  M. Lazdunski,et al.  K+ channel openers prevent global ischemia-induced expression of c-fos, c-jun, heat shock protein, and amyloid beta-protein precursor genes and neuronal death in rat hippocampus. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  E. Raftery,et al.  Comparison of nicorandil and atenolol in stable angina pectoris. , 1990, The American journal of cardiology.

[41]  J. Tijssen,et al.  Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study. , 1992, Journal of cardiovascular pharmacology.

[42]  K. Fox,et al.  Potassium channel openers in myocardial ischaemia - clinical experience with nicorandil , 1999 .

[43]  E. Marbán,et al.  Nicorandil , 2024, Reactions Weekly.

[44]  K. Kasono,et al.  Nicorandil improves diabetes and rat islet beta-cell damage induced by streptozotocin in vivo and in vitro. , 2004, European journal of endocrinology.

[45]  M. Saito,et al.  Nicorandil ameliorates ischaemia‐reperfusion injury in the rat kidney , 2011, British journal of pharmacology.

[46]  W. Hillis,et al.  Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial , 2002, The Lancet.

[47]  T. Nakagawa,et al.  Nicorandil, a K(atp) channel opener, alleviates chronic renal injury by targeting podocytes and macrophages. , 2012, American journal of physiology. Renal physiology.

[48]  T. Shiga,et al.  Intravenous nicorandil prevents thiamylal-fentanyl–induced bronchoconstriction in humans* , 2003, Critical care medicine.